8-K: Masimo Issues Supplemental Proxy for Danaher Merger

Masimo Corporation has filed supplemental disclosures to its definitive proxy statement regarding the pending merger with Danaher Corporation to address ongoing stockholder litigation.

Summary

• Masimo is providing supplemental information to its April 1, 2026, definitive proxy statement regarding the proposed merger with Danaher Corporation.
• The supplement addresses claims made in three separate stockholder lawsuits and various demand letters alleging that the original proxy statement was inaccurate or incomplete.
• The company maintains that the claims are without merit but is providing the additional disclosures to mitigate litigation risks and potential delays to the merger.
• The supplemental information includes additional background on the sale process, including previous outreach to potential acquirors and details on financial advisor Centerview Partners' valuation analyses.
• The special meeting of stockholders remains scheduled for May 1, 2026, and the board continues to recommend a vote in favor of the merger.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral development; while the supplemental disclosures provide transparency, the presence of multiple lawsuits and the need to address them highlights friction in the merger process.

Positives

• The company is taking proactive steps to resolve litigation and avoid potential delays to the merger.
• The board of directors maintains its recommendation for stockholders to vote in favor of the merger.
• The supplemental disclosures provide increased transparency regarding the historical sale process and valuation methodologies used by financial advisors.

Negatives

• The company is facing multiple lawsuits from stockholders challenging the adequacy of disclosures in the proxy statement.
• The merger process has been subject to scrutiny regarding the background of the sale and the valuation process.
• The company previously faced challenges in finding acquirors in 2023 due to litigation risks and exposure to non-healthcare consumer businesses.

Risks

• Potential for further litigation or additional lawsuits challenging the merger or the adequacy of disclosures.
• Risk that the merger may not be completed on the anticipated terms, in a timely manner, or at all.
• Failure to satisfy conditions to the consummation of the merger, including obtaining necessary stockholder approval.
• Potential for regulatory hurdles or conditions placed on approvals.
• Diversion of management attention from ongoing business operations during the pendency of the merger.

Future Outlook

The company is focused on completing the merger with Danaher as scheduled on May 1, 2026, subject to stockholder approval and other customary closing conditions.

Management Comments

• The Board continues to recommend that you vote FOR each of the proposals to be voted on at the Special Meeting.
• Masimo believes that the claims in the Actions and the Stockholder Letters are without merit, that the Definitive Proxy Statement complies with applicable law and that no further disclosure is required.
• Masimo specifically denies all allegations in the Actions and the Stockholder Letters and any assertion that additional disclosure was or is required.

Industry Context

StockSavvy.ai notes that this filing reflects the common trend of 'deal litigation' in the healthcare and medical technology sectors, where stockholders frequently challenge the adequacy of proxy disclosures in an attempt to secure better terms or force supplemental information before a merger vote.

Comparison to Industry Standards

• The valuation multiples provided in the precedent transactions analysis (ranging from 13.4x to 27.4x LTM EBITDA) are consistent with historical M&A activity in the medical device and healthcare technology sectors.
• The use of supplemental disclosures to moot litigation is a standard legal strategy employed by companies to avoid injunctions and ensure the timely closing of a merger.

Corporate Governance

Legal Proceedings

• Ed Smith v. Masimo Corporation et al., Index No. 652084/2026 (Supreme Court of New York).
• Richard McDaniel v. Masimo Corporation et al., Index No. 65117/2026 (Supreme Court of New York).
• Donald Kendig v. Brennan et al., Case No. 26-CIV-02902 (Superior Court of California).
• Various demand letters from stockholders alleging deficient disclosures.

Stakeholder Impact

• Stockholders are provided with additional information to consider before the upcoming vote.
• The merger process faces potential risks from ongoing litigation, though the company is taking steps to mitigate these.

Next Steps

• Hold the special meeting of stockholders on May 1, 2026.
• Continue to defend against pending litigation related to the merger.

Key Dates

Keywords

Masimo, Danaher, Merger, Proxy Statement, Stockholder Litigation, Acquisition, Corporate Governance